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ABSTRACT
Background and Aims Previous studies have reported that people who use a smoking cessation medication while
smoking and reduce cigarette consumption spontaneously are three times more likely to stop smoking after a quit date.
The aimwas to replicate this and assess whether it arises because of willed effortful reduction rather than unwilled reduced
drive to smoke caused bymedication.Design Secondary analysis of a trial where participants were randomised to smoke
as normal or reduce by 75% over 2 weeks prior to quit date, using nicotine replacement therapy (NRT) in both arms.
Setting Thirty-one UK primary care practices. Participants A total of 517 adult smokers seeking quitting support
in the carbon monoxide (CO) analyses and 421 in the cigarettes/day analyses.Measurements Russell Standard absti-
nencewas recorded 4weeks after quit date. The randomized groupswere combined and the association between reduction
and abstinence examined. The second analysis assessed whether this association differed by whether smokers were, or
were not, instructed to reduce. Findings In all participants, there was no evidence that reducing cigarettes/day or CO
by at least half compared with not reducing predicted abstinence at 4 weeks [risk ratio (RR) = 0.88; 95% conﬁdence
interval (CI) = 0.68–1.14 and RR = 1.20; 95% CI = 1.00–1.44, respectively]. However, in smokers instructed to reduce,
CO reduction was associated with 4-week abstinence (RR = 1.52; 95% CI = 1.16–2.00), but not among people advised
not to reduce (RR = 0.91; 95% CI = 0.67–1.24). Conclusions Smoking reduction prior to a target quit date while on a
smoking cessation medication may only predict subsequent abstinence when smokers are consciously attempting to reduce.
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INTRODUCTION
An important problem for the science and practice of
smoking cessation is that there appears to be little basis
for matching treatments to particular patients. One prom-
ising approach that might allow personalization could be
for smokers to try medication prior to attempting to stop
smoking and to choosemedication based on their response.
Response to medication may be indicated by spontaneous
reduction in smoking, either by reduced daily consumption
of cigarettes or other markers of smoke intake, such as
concentration of exhaled carbon monoxide or cotinine
concentration.
Several studies have examined whether or not sponta-
neous smoking reduction while using smoking cessation
medication is associated with a higher likelihood of quitting
smokingafter a quit date. In four of these trials, participants
used nicotine replacement therapy (NRT) for 2 weeks prior
to quitting [1–4]. Participants who reduced consumption
by more than the median (56%) while smoking and using
NRT were found in one study to be more than three times
more likely to stop smoking than people reducing less than
the median [3]. Similarly, in people using varenicline for
4weeks prior to quit day, those who reduced consumption
(indicated by cotinine concentration) by more than 50%
were approximately three times more likely to achieve
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abstinence than those not reducing by this amount [5].
However, in three cases of the aforementioned studies
[1,2,5] observations were post hoc, which makes inter-
pretation difﬁcult. Evidence in a similar ﬁeld suggests that
initial ﬁndings of observational associations tend to over-
estimate the strength of association [6].
The ﬁrst aim of this study is to conduct a planned repli-
cation study to examine whether smoking reduction while
using cessation medication prior to quit date predicts absti-
nence. The second aim is to examine two plausible mecha-
nisms that might explain this association. The explanation
favoured by the investigators in the aforementioned studies
[1–3,5] is that smoking reduction is unwilled and occurs
because medication met the need to smoke, and hence will
support smokers adequately after they try to stop smoking.
However, there is a second possible explanation. The inves-
tigators in these previous studies advised participants to
smoke freely. It could be that participants on cessation
medication chose to try to reduce their smoking. Accord-
ing to this explanation, participants who were successful
at controlling their smoking and manifesting a reduction
would become successful when they try to quit because
the same forces are at play during successful reduction as
successful cessation. In support of this, a systematic review
suggests that successful willed reduction is associated caus-
ally with subsequent cessation [7]. We exploited the design
of a recent trial to examine these competing explanations.
METHOD
Data source and permissions
Data were obtained through a non-inferiority randomized
controlled trial (RCT) of abrupt cessation versus smoking re-
duction prior to cessation conducted in England from 2009
to 2012 (trial registration number: ISRCTN22526020) [8].
The main ﬁnding of the trial was that abrupt quitting
resulted in superior 4-week quit rates to quitting smoking
following smoking reduction [relative risk (RR) = 0.80;
95% conﬁdence interval (CI) = 0.67, 0.95]. The trial was
authorized by the National Research Ethics Committee, the
Medicines and Healthcare products Regulatory Agency
and local NHS Research and Development ofﬁces. Separate
permissions were not required for this analysis.
Design
The Rapid Reduction Trial (RRT) was a randomized, non-
inferiority trial of 697 participants with two trial arms. In
the reduction trial arm participants were asked to reduce
their smoking to 50% of their baseline rate in the ﬁrst week
after baseline, and to 75% of their baseline smoking rate in
the second week following baseline, before quitting
completely. Participants were advised to choose and follow
one of three structured reduction plans. More details of
thesemethods are available in the trial protocol [8]. During
the 2-week pre-quit phase, reducers used nicotine patches
(21mg, reducing to 14mg in the event of intolerance to the
higher dose) and an acute form of NRT (i.e. gum, lozenge
etc.) to compensate for the missed cigarettes. In the abrupt
trial arm participants were also asked to set a quit day for
2 weeks after baseline, but were advised to smoke as they
usuallywould and not reduce for the 2weeks before quitting
completely. In this group participants used nicotine patches
only (21 or 14 mg) prior to the quit date. We did not give
participants acute NRT, as this group were not intentionally
trying to reduce smoking.
In both groups participants were provided with weekly
behavioural support from 2 weeks prior to quit day to
4 weeks after quit day and then again at 8 weeks. In the
2 weeks prior to quit day, the reduction group discussed re-
duction strategies and progress made, and we addressed
barriers to reduction. In the abrupt arm participants were
prepared for quitting by asking them to think about scenar-
ios that they may ﬁnd difﬁcult after the quit day and think-
ing of potential ways to deal with these if they should arise.
After quit day, the treatment in both arms was identical.
Participants used combination NRT (i.e. 21-mg nicotine
patches and an acute form of NRT) with weekly behav-
ioural support focused on dealing with cravings and with-
drawal and preventing relapse.
We exploited this design in an observational analysis to
examine our competing hypotheses. First, we examined
overall whether degree of reduction while smoking and
using NRT was associated with future cessation. Secondly,
we used the difference in instructions by trial arm to exam-
ine the degree to which intentional reduction was associ-
ated with cessation success. In the abrupt arm, the
instruction was ‘try to smoke as normal’ but, as antici-
pated, not everyone could smoke the same number of
cigarettes while using NRT. People who reduced despite ad-
vice to smoke the same number were probably doing so be-
cause they felt impelled to do so by the medication effect. In
the other (reduction) arm, the instruction was to try to re-
duce smoking, and therefore the degree of reduction in this
arm probably represents the ability to achieve intentional
control over smoking. This difference in instruction differen-
tiates between competing hypotheses in the way that the
ad-libitum smoking instruction in previous studies has not.
Participants
Twenty-three nurses recruited people who smoked in 31
primary care practices in the West Midlands of England.
Randomization was stratiﬁed by nurse and each nurse
randomized between 6 and 120 participants. General prac-
titioners (GPs) wrote to their patients who smoked asking
them if theywould like to quit smokingand, if so, to contact
the trial team. Trial clinics took place in participants’ GP
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practices. Participants were eligible if they met the following
criteria: smoking at least 15 cigarettes per day (CPD); willing
to stop smoking completely in 2weeks; not currently under-
going any other treatment to stop smoking; and no medical
reasons that would mean concurrent smoking and use of
NRT was inadvisable. Almost all people with medical,
psychiatric and comorbid substance use problems were
enrolled.
Variables
The following variables collected during RRTwere relevant
to the reported analysis.
Reduction in smoking
We measured the number of cigarettes smoked and the
concentration of exhaled carbon monoxide (CO) at base-
line (visit 1) and in the following 2 weeks, prior to quit
day (at visit 2; a week after baseline; and visit 3, 2 weeks
after baseline, the day before quit day). For each partici-
pant we calculated the percentage change in baseline
CPD and CO between visits 1 and 3. We also dichotomized
these variables because reduction by at least 50% has been
used previously as, or has been found to be, an indicator of
response to medications in research studies [3,5].
Smoking cessation
Abstinence data were collected at 4-week and 6-month
follow-ups (measured from quit day). In both cases absti-
nence was deﬁned using the Russell Standard (RS)
approach—intention-to-treat, assuming those lost to
follow-up resumed smoking, allowing a grace period of
2 weeks after quit day, with no more than ﬁve cigarettes
smoked thereafter, and validated by an exhaled CO reading
of <10 parts per million (p.p.m.) [9].
Potential confounders
The following variables were potential confounders, as they
may be associated with the likelihood of smoking cessation:
gender; age (in years); ethnicity (dichotomized as white eth-
nicity or other); post-school qualiﬁcation (dichotomized as
having a post-school qualiﬁcation or not); employment
(dichotomized as in paid employment or not); age started
smoking (in years); nicotine dependence at baseline [mea-
sured using the Fagerström Test for Cigarette Dependence
(FTCD)] [10,11]; baseline saliva cotinine (measured in
ng/ml); number of previous quit attempts; length of longest
abstinence achieved in a previous quit attempt (dichoto-
mized as less than a month or longer); living with smoker
or not; conﬁdence in quitting at baseline (measured on the
following response scale: low, not very high, quite high, very
high, extremely high); trial arm (reduction versus abrupt);
and pre-randomization trial arm preference (reduction
arm, abrupt arm, no preference).
Analysis
Some people did not complete the daily diary, which
recorded cigarette consumption, and hence data on reduc-
tion in cigarettes were missing. Some did not attend the
visit 2 weeks after baseline (the day before quit day), and
hence data on CO reduction were missing. We examined
whether there were systematic differences between the
people who did not supply data on reduction and those
who did by comparing medians and proportions using χ2
tests for categorical baseline variables and Mann–Whitney
U-tests for ordinal or continuous variables.
The strength of association between change in smoking
measured using CO and CPD and abstinence at 4 weeks
and 6 months was explored. We present relative risks with
95% CIs due to the high incidence of abstinence (> 10%),
using a modiﬁed Poisson generalized estimating equation
using the glm command in STATA [12]. Models were run
with CO and CPD as continuous variables and dichoto-
mized variables. These analyses were repeated adjusting
for potential confounders. The impact of the nurse (the
stratiﬁcation factor in the trial) was explored in the main
trial analyses, and no evidence of clustering was found;
therefore it was not adjusted for in this analysis.
We examined whether the strength of association dif-
fered by trial arm by including appropriate multiplicative
interaction terms for the continuous reduction variables.
As multiple tests were carried out, a P-value of 0.01 or less
indicated a signiﬁcant interaction. Regardless of the signif-
icance of this term, we presented the strength of the associ-
ation by trial arm. We could not include the interaction
term for the dichotomous reduction measures due to high
collinearity, and so insteadwe ran separatemodels for each
trial arm to produce relative risk estimates.
RESULTS
Baseline characteristics of those in the analyses
A total of 697 participants were enrolled into the trial and
therefore provided baseline data. There were some differ-
ences between the whole population recruited and the
sample who supplied data on reduction and were included
in these analyses. Participants supplying data for the current
analyses [421 (60.4%) for the CPD analyses and 517
(74.2%) participants for the CO analyses] were slightly more
likely to be allocated to the abrupt trial arm (CPD 56.3%; CO
56.3 versus 50.9% of the total participants randomized into
the trial) (Table 1). Also, as expected, people not attending
clinic visits prior to quit day or not completing diaries were
less likely to achieve abstinence; therefore the abstinence
rates in the samples used in the current analyses are higher
than those observed in the total trial sample.
We compared those who supplied data for these analy-
ses to those who did not do so. People supplying data were
Does cigarette reduction predict abstinence? 3
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
Ta
bl
e
1
Pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
s.
A
ll
ra
nd
om
iz
ed
pa
rt
ic
ip
an
ts
CP
D
an
al
ys
is
CO
an
al
ys
is
B
as
el
in
e
pa
rt
ic
ip
an
t
ch
ar
ac
te
ri
st
ic
To
ta
l
(n
=
69
7)
a
A
br
up
t
ar
m
(n
=
35
5)
R
ed
uc
tio
n
ar
m
(n
=
34
2)
To
ta
l
(n
=
42
1)
a
R
ed
uc
ed
<
50
%
(n
=
20
8)
a
R
ed
uc
ed
≥5
0%
(n
=
21
3)
a
To
ta
l
(n
=
51
7)
a
R
ed
uc
ed
<
50
%
(n
=
33
6)
a
R
ed
uc
ed
≥5
0%
(n
=
18
1)
a
A
br
up
t
tr
ia
la
rm
,n
/N
(%
)
35
5/
69
7
(5
0.
9)
35
5/
35
5
(1
00
.0
)
0/
34
2
(0
.0
%
)
23
7/
42
1
(5
6.
3)
18
5/
20
8
(8
8.
9)
52
/2
13
(2
4.
4)
29
1/
51
7
(5
6.
3)
24
2/
33
6
(7
2.
0)
49
/1
81
(2
7.
1)
A
ge
,m
ed
ia
n
(I
Q
R
)
49
.0
(1
7.
0)
49
.0
(1
7.
0)
49
.0
(1
7.
3)
50
.0
(1
8.
0)
50
.0
(1
7.
0)
50
.0
(1
9.
0)
50
(1
8)
50
.0
(1
7.
0)
48
.0
(1
7.
5)
M
al
e
ge
nd
er
,n
/N
(%
)
35
0/
69
7
(5
0.
2)
17
5/
35
5
(4
9.
3)
17
5/
34
2
(5
1.
2)
23
4/
42
1
(5
5.
6)
11
4/
20
8
(5
4.
8)
12
0/
21
3
(5
6.
3)
27
6/
51
7
(5
3.
4)
17
7/
33
6
(5
2.
7)
99
/1
81
(5
4.
7)
W
hi
te
et
hn
ic
ity
,n
/N
(%
)
64
8/
69
2
(9
3.
6)
32
9/
35
1
(9
3.
7)
31
9/
34
1
(9
3.
5)
39
8/
41
9
(9
5.
0)
19
8/
20
6
(9
6.
1)
20
0/
21
3
(9
3.
9)
48
0/
51
3
(9
3.
6)
31
3/
33
3
(9
4.
0)
16
7/
18
0
(9
2.
8)
Po
st
-s
ec
on
da
ry
sc
ho
ol
(1
5/
16
ye
ar
s)
ed
uc
at
io
na
l
qu
al
iﬁ
ca
tio
n,
n/
N
(%
)
34
5/
67
8
(5
0.
9)
18
5/
34
8
(5
3.
2)
16
0/
33
0
(4
8.
5)
21
5/
41
0
(5
2.
4)
11
0/
20
2
(5
4.
5)
10
5/
20
8
(5
0.
5)
25
9/
50
5
(5
1.
3)
16
4/
33
2
(4
9.
4)
95
/1
73
(5
4.
9)
In
pa
id
em
pl
oy
m
en
t,
n/
N
(%
)
38
2/
69
1
(5
5.
3)
19
2/
35
1
(5
4.
7)
19
0/
34
0
(5
5.
9)
24
0/
41
9
(5
7.
3)
11
2/
20
6
(5
4.
4)
12
8/
21
3
(6
0.
1)
29
8/
51
3
(5
8.
1)
18
7/
33
3
(5
6.
2)
11
1/
18
0
(6
1.
7)
A
ge
st
ar
te
d
sm
ok
in
g
(y
ea
rs
),
m
ed
ia
n
(I
Q
R
)
16
.0
(4
.0
)
16
.0
(4
.0
)
16
.0
(3
.0
)
16
.0
(3
.0
)
16
.0
(3
)
16
.0
(3
)
16
.0
(3
.0
)
16
.0
(3
.0
)
16
.0
(3
.0
)
Li
ve
s
w
ith
sm
ok
er
,n
/N
(%
)
26
6/
68
8
(3
8.
7)
15
0/
35
3
(4
2.
5)
11
6/
33
5
(3
4.
6)
16
0/
41
8
(3
8.
3)
11
8/
20
6
(5
7.
3)
14
0/
21
2
(6
6.
0)
19
6/
51
4
(3
8.
1)
13
9/
33
4
(4
1.
6)
57
/1
80
(3
1.
7)
N
um
be
r
of
pr
ev
io
us
qu
it
at
te
m
pt
s,
m
ed
ia
n
(I
Q
R
)
2.
0
(2
.0
)
2.
0
(3
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
2.
0
(2
.0
)
Lo
ng
es
t
pr
ev
io
us
qu
it
at
te
m
pt
<
a
m
on
th
,n
/N
(%
)
27
5/
66
0
(4
1.
7)
14
4/
33
7
(4
2.
7)
13
1/
32
3
(4
0.
6)
16
7/
39
8
(4
2.
0)
82
/1
97
(4
1.
6)
85
/2
01
(4
2.
3)
20
4/
49
0
(5
8.
4)
13
5/
31
8
(4
2.
5)
69
/1
72
(4
0.
1)
Lo
ng
es
t
pr
ev
io
us
qu
it
at
te
m
pt
≥
a
m
on
th
,n
/N
(%
)
38
5/
66
0
(5
8.
3)
19
3/
33
7
(5
7.
3)
19
2/
32
3
(5
9.
4)
23
1/
39
8
(5
8.
0)
11
5/
19
7
(5
8.
4)
11
6/
20
1
(5
7.
7)
28
6/
49
0
(5
8.
4)
18
3/
31
8
(5
7.
5)
10
3/
17
2
(5
9.
9)
Sa
liv
ar
y
co
tin
in
e
co
nc
en
tr
at
io
n
(n
g/
m
l),
m
ed
ia
n
(I
Q
R
)
35
8.
5
(2
12
.7
)
34
9.
5
(1
97
.7
)
36
5.
3
(2
34
.5
)
36
7.
5
(2
01
.0
)
37
9.
2
(1
83
.9
)
36
5.
2
(2
18
.5
)
36
0.
3
(2
00
.8
)
36
7.
2
(2
00
.3
)
35
2.
4
(2
08
.3
)
Ci
ga
re
tt
es
pe
r
da
y
(C
PD
),
m
ed
ia
n
(I
Q
R
)
20
.0
(1
0.
0)
20
.0
(9
.0
)
20
.0
(1
0.
0)
20
.0
(1
0.
0)
20
.0
(8
.0
)
20
.0
(1
0.
0)
20
.0
(1
0.
0)
20
.0
(8
.0
)
20
.0
(7
.0
)
Fa
ge
rs
tr
öm
Te
st
fo
r
N
ic
ot
in
e
D
ep
en
de
nc
e
(F
TN
D
)s
co
re
,m
ed
ia
n
(I
Q
R
)b
6.
0
(3
.0
)
6.
0
(3
.0
)
6.
0
(3
.0
)
5.
0
(3
.0
)
6.
0
(3
)
5.
0
(3
)
6.
0
(3
.0
)
6.
0
(3
)
5.
0
(3
)
Pr
ef
er
en
ce
fo
r
ab
ru
pt
tr
ea
tm
en
t
ar
m
,n
/N
(%
)
22
4/
69
7
(3
2.
1)
11
7/
35
5
(3
3.
0)
10
7/
34
2
(3
1.
3)
12
6/
42
0
(3
0.
0)
60
/2
07
(2
9.
0)
66
/2
13
(3
1.
0)
16
6/
51
6
(3
2.
2)
11
0/
33
5
(3
2.
8)
56
/1
81
(3
0.
9)
Pr
ef
er
en
ce
fo
r
gr
ad
ua
l
tr
ea
tm
en
t
ar
m
,n
/N
(%
)
35
5/
69
7(
50
.9
)
17
6/
35
5
(4
9.
6)
17
9/
34
2
(5
2.
3)
21
4/
42
0
(5
1.
0)
10
6/
20
7
(5
1.
2)
10
8/
21
3
(5
0.
7)
25
5/
51
6
(4
9.
4)
16
2/
33
5
(4
8.
4)
93
/1
81
(5
1.
4)
N
o
tr
ia
la
rm
pr
ef
er
en
ce
,n
/N
(%
)
11
8/
69
7
(1
6.
9)
62
/3
55
(1
7.
5)
56
/3
42
(1
6.
4)
80
/4
20
(1
9.
0)
41
/2
07
(1
9.
8)
39
/2
13
(1
8.
3)
95
/5
16
(1
8.
4)
63
/3
35
(1
8.
8)
32
/1
81
(1
7.
7)
Co
nﬁ
de
nc
e
in
qu
itt
in
g,
m
ed
ia
n
(I
Q
R
)c
4.
0
(1
.0
)
4.
0
(1
.0
)
4.
0
(1
.0
)
4.
0
(1
.0
)
4.
0
(1
.0
)
4.
0
(1
.0
)
4
(1
.0
)
4.
0
(1
.0
)
4.
0
(1
.0
)
a N
um
be
rs
of
pa
rt
ic
ip
an
ts
us
ed
to
ca
lc
ul
at
e
st
at
is
tic
s
fo
r
ea
ch
va
ri
ab
le
va
ry
du
e
to
m
is
si
ng
da
ta
.b
R
an
ge
fr
om
0
to
10
,w
he
re
10
=
hi
gh
es
t
le
ve
lo
fd
ep
en
de
nc
e.
c M
ea
su
re
d
on
a
sc
al
e
fr
om
1
to
6,
w
he
re
1
=
ve
ry
lo
w
an
d
6
=
ex
tr
em
el
y
hi
gh
.
IQ
R
=
in
te
rq
ua
rt
ile
ra
ng
e;
CO
=
ca
rb
on
m
on
ox
id
e;
CP
D
=
ci
ga
re
tt
es
pe
r
da
y;
FT
N
D
=
Fa
ge
rs
tr
om
Te
st
fo
r
N
ic
ot
in
e
D
ep
en
de
nc
e.
4 Nicola Lindson-Hawley et al.
© 2016 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
signiﬁcantly more likely to be male for both the CPD and
CO analyses (CPD 55.6 versus 42.0%male; CO 53.4 versus
41.1%) and less heavily dependent upon cigarettes in the
CO analysis only (median FTND 5 versus median FTND 6).
In the case of both the CPD and CO analyses, just more
than half the participants were male (234 of 421, 55.6%
and 276 of 517, 53.4%, respectively), the average age
was 50 years in both groups, participants had an average
baseline salivary cotinine concentration of 368 and
360 ng/ml and an FTND of 5 and 6, respectively (Table 1).
At 4-week follow-up 240 of 421 (57.0%) participants were
abstinent in the CPD analysis and 289 of 517 (55.9%) in
the CO analysis, and at 6-month follow-up 100 of 421
(23.8%) in the CPD analysis and 118 of 517 (22.8%) in
the CO analysis (Table 2).
Association between pre-cessation reduction and
abstinence in the whole sample
Participants randomized to the reduction arm of the trial re-
duced cigarette consumption and exhaled CO levels during
the 2 weeks by a mean of 69 and 47%, respectively. Partici-
pants randomized to the abrupt arm also reduced their
consumption by a mean of 29 and 21%. Participants in
the reduction arm were more likely to drop out prior to quit
day, probably because theywere failing to achieve reduction.
There was no association between reduced cigarette
consumption and smoking abstinence at 4 weeks or
6 months (Table 3). At 4 weeks, 124 of 213 (58.2%) par-
ticipants who reduced their CPD by at least 50% and 116
of 208 (55.8%) of participants who reduced their CPD by
less than 50% were abstinent, and at 6 months 50 of
213 (23.5%) participants who reduced their CPD by at
least 50% and 50 of 208 (24.0%) of participants who
reduced their CPD by less than 50% were abstinent.
There was a modest signiﬁcant association between
the degree of reduction in exhaled CO levels and smoking
abstinence at 4-week follow-up. For every 10% reduction
in baseline CO participants achieved, the likelihood of ces-
sation at 4 weeks increased by 4% after adjustment.
Dichotomizing change in CO to more than 50% reduction
or less showed that at 4 weeks, 112 of 181 (61.9%) partic-
ipants who reduced their CO by at least 50% and 177 of
336 (52.7%) participants who reduced their CO by less
than 50% were abstinent; the difference was not signiﬁ-
cant before or after adjustment. Therewere no associations
Table 2 Reduction and abstinence outcomes in the whole sample.
Participant smoking outcome All (n = 697)a CPD analysis (n = 421)a CO analysis (n = 517)a
Average percentage CPD reduction over
pre-quit period, median (IQR)
49.0 (48.9) 50.0 (50.3) 49.0 (48.9)
Reduced CPD by ≥50% during pre-quit
period, n/N (%)
213/421 (30.6) 213/421 (50.6) 200/400 (50.0)
Average percentage CO reduction over
pre-quit period, median (IQR)
35.7 (50.2) 35.7 (50.2) 34.5 (51.5)
Reduced exhaled CO by ≥50% during
pre-quit period, n/N (%)
181/517 (26.0) 142/400 (35.5) 181/517 (35.0)
Abstinent at 4 weeks post-quit, n/N (%) 308/697 (44.2) 240/421 (57.0) 289/517 (55.9)
Abstinent at 6 months post-quit, n/N (%) 131/697 (18.8) 100/421 (23.8) 118/517 (22.8)
CPD = cigarettes per day; CO = carbon monoxide; IQR = interquartile range. aNumbers of participants used to calculate statistics for each variable vary due to
missing data.
Table 3 The association between reduction over a 2-week pre-quit period and smoking abstinence at 4 weeks and 6 months post-quit.
Relative risk (RR) of abstinence at 4 week follow-up
RR (95% CI)
RR of abstinence at 6 month follow-up
RR (95% CI)
Unadjusted analyses Adjusted analysesa Unadjusted analyses Adjusted analysesa
Reduction in CPDb 1.02 (0.99–1.05) 1.01 (0.97–1.05) 1.02 (0.96–1.07) 1.00 (0.93–1.08)
At least 50% reduction in CPD 1.04 (0.88–1.23) 0.88 (0.68–1.14) 0.98 (0.69–1.38) 0.76 (0.45–1.29)
Reduction in COc 1.02 (0.99–1.04) 1.04 (1.01–1.06) 1.01 (0.98– 1.05) 1.01 (0.96–1.06)
At least 50% reduction in CO 1.17 (1.01–1.37) 1.20 (1.00–1.44) 1.23 (0.89–1.69) 1.39 (0.97–2.00)
aAll adjusted for gender; age; ethnicity; post-school qualiﬁcation; employment; age started smoking; Fagerstrom Test for Nicotine Dependence score; baseline
saliva cotinine (measured in ng/ml); number of previous quit attempts; length of longest quit attempt; living with smoker; conﬁdence in quitting at baseline;
trial arm; pre-randomization trial arm preference. bRelative risk presented for a 10% cigarette per day reduction. cRelative risk presented for a 10% reduction in
CO. RR = relative risk; CI = conﬁdence intervals; CPD = cigarettes per day; CO = carbon monoxide.
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with 6-month abstinence. At 6months, 47 of 181 (26.0%)
participants who reduced their CO by at least 50% and 71
of 336 (21.1%) participants who reduced their CO by less
than 50% were abstinent.
Do the different instructions modify the association
between reduction and subsequent cessation?
There was no statistically signiﬁcant evidence that the
instructions given to participants in each trial arm modi-
ﬁed the strength of association between degree of reduction
and subsequent cessation (Table 4). None the less, it is
noteworthy that the risk ratio was larger in the reduction
arm than the abrupt arm in all eight comparisons. In the
abrupt arm, which represented normal smoking cessation
practice, there was no evidence of an association between
reduction and subsequent cessation. This was apparent
only in the reduction arm on some measures: the arm in
which participants were aiming to reduce.
DISCUSSION
In this planned replication study there was little evidence
overall that smoking reduction while using nicotine
replacement therapy and smoking predicted subsequent
abstinence. We hypothesized that the association between
reduction and quitting reported previously [1–3,5] could
have arisen, because people felt that they ought to reduce
smoking intentionally while using cessation medication.
We did not ﬁnd strong evidence that the strength of associ-
ation between reduction and cessation varied by trial arm.
Nevertheless, an association between reduction and subse-
quent cessation was manifest in the condition where
participants deliberately reduced their smoking.
An important strength of this study is that it is a
planned replication of previous post-hoc ﬁndings. As in
the other studies, this is an observational analysis compar-
ing naturally occurring groups (reducers with non-
reducers across trial arms), albeit within the setting of an
RCT, and therefore subject to potential for confounding.
However, we adjusted for many potential confounders
and adjustment did not change the ﬁndings greatly, so it
is unlikely that confounding obscured the association
between reduction and subsequent cessation. It may have
been that the instruction to participants in the abrupt
arm to smoke as normal may have deterred medication
use, but there was no evidence of this. Patch use was very
similar in both trial arms,with between 80 and 90% of par-
ticipants using their patches daily. Additionally, our advice
to smoke as usual in the abrupt cessation arm may have
prevented reduction being manifest. Despite this advice,
however, 81 and 69% of the participants in this arm
reduced CPD and CO, respectively, suggesting that our ad-
vice did not prevent reduction. Finally, we have inferred that
people in the reduction arm achieved their reduction partly
through efforts to do so, and not through the additional
short-actingNRTavailable in this arm.We believe this is rea-
sonable, given that the typical dose was two pieces of
gum/lozenge per day. We have also inferred that people
who reduced in the arm who were advised that it would
be helpful not to reduce were doing so because they felt a
reduced drive to smoke engendered by the medication,
rather than because theywere wilfully doing so. These infer-
ences seem logical, but are not supported by direct observa-
tions of whether people were trying to reduce or not.
The trial followed participants to 6 months after quit-
ting, which allowed us to ascertain that, although there
was one signiﬁcant association between reduction and
Table 4 The adjusted association between smoking reduction and abstinence at 4weeks and 6months post-quit, split by trial arm (abrupt
versus reduction).
4-week follow-up 6-month follow-up
Risk of abstinence
in abrupt arm
RR (95% CI)
Risk of abstinence
in reduction arm
RR (95% CI)
Signiﬁcance of
interaction
effect trial
arm × reduction
Risk of abstinence
in abrupt arm
RR (95% CI)
Risk of abstinence
in reduction arm
RR (95% CI)
Signiﬁcance
of interaction
effect trial
arm × reduction
Reduction in
CPDa
0.99 (0.95–1.04) 1.06 (0.98–1.15) P = 0.17 0.98 (0.84–1.14) 1.00 (0.92–1.10) P = 0.75
At least 50%
reduction in CPDb
0.77 (0.55–1.06) 1.10 (0.66–1.85) NA 0.60 (0.28–1.26) 1.09 (0.41–2.92) NA
Reduction in COc 1.02 (0.99–1.05) 1.06 (1.02–0.11) P = 0.09 0.99 (0.94–1.05) 1.05 (0.93–1.18) P = 0.41
At least 50%
reduction in COb
0.91 (0.67–1.24) 1.52 (1.16–2.00) NA 0.86 (0.46–1.60) 2.17 (1.13–4.16) NA
aRelative risk presented for a 10% cigarette per day reduction. bInteraction term could not be included due to collinearity and therefore separate models were
run for each trial arm. cRelative risk presented for a 10% reduction in CO. RR = relative risk; CI = conﬁdence intervals; CPD = cigarettes per day; CO = carbon
monoxide; NA = not available.
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cessation at 4 weeks, this was not observed at 6 months.
Therefore, this may have been a chance ﬁnding. The esti-
mates were precise enough to exclude effects of the size
reported previously, which suggested a threefold difference
in the likelihood of achieving abstinence [3,5].
The cut-off used to identify responders to medication is
a 50% reduction, based on a median split used previously
in one study [3] and rounded to 50% in another [5]. We
also examined change in CPD and CO as continuous vari-
ables, which generally showed no relationship with cessa-
tion. Our ﬁndings stand in stark contrast to these
previous ﬁndings, in showing no overall evidence of a
relationship between reduction and subsequent cessation
while using smoking cessationmedication. Unlike previous
studies, the design of our trial allowed us to split the sample
into those who were reducing because they felt impelled to
do so by medication and those who were trying to reduce.
In the main, previous studies have instructed participants
to smoke freely. By so doing, we found that the association
seemed to be apparent only among those who were trying
to reduce. This raises the possibility that the ﬁndings in
these previous studies may have been due to people trying
to reduce. It seems likely that people who can control their
smoking more successfully when reducing can enact these
same strategies to abstain completely after quit day.
The best evidence that smoking reduction on medica-
tion indicates a higher likelihood of achieving abstinence
would come from an adaptive clinical trial. In such a trial,
smokers who want to quit smoking would try several ces-
sation medications to identify the one to which they re-
spond by reducing when allowed to smoke freely. This
would be compared with a non-adaptive treatment ap-
proach, where cessation medication is picked at random.
There are two such adaptive trials [4,13]; the ﬁrst random-
ized people who did not reduce consumption by 50%while
using a nicotine patch to quit on a nicotine patch, add
bupropion to the patch or switch to varenicline [4]. The
quit rates on both varenicline and bupropion plus NRT
were higher, but this was signiﬁcant only in the bupropion
condition. However, these results are clouded by the fact
that evidence suggests there may be a beneﬁt of bupropion
plus NRTover NRT alone (although this is uncertain) [14],
and that varenicline appears to be more effective than NRT
[15], suggesting that the results may be due to more efﬁca-
cious medication per se rather than tailoring to the re-
sponse to NRT itself. In the second trial, participants were
asked to use varenicline for 3 weeks prior to quitting [13].
Those in whom smoking was not suppressed were ran-
domized to either continue on the standard dose or have
the dose of varenicline increased. There was no evidence
of beneﬁt from dose escalation. Our results may help to
explain this. The initial observations, that smoking reduc-
tion while smoking freely and using pharmacotherapy
was associated with subsequent cessation, may have been
published because the association was unexpectedly large,
but also plausible and potentially useful. Our planned rep-
lication suggests that this marker may be a weak predictor
of response to medication, and it may not be as useful as
ﬁrst thought, in line with the trial ﬁndings.
It is important to note what we are not saying with
these data. We observed that people advised to reduce
and who did so appeared more likely to go on to quit
smoking, while people who were instructed to maintain
but in fact reduced were not more likely to quit smoking.
It could be surmised that advising people to reduce while
using pre-quit NRT is helpful and advising people not to
reduce is unhelpful, but this would be incorrect. The trial
from which these data are obtained showed that people
randomized to the arm in which people were advised to
try to smoke as normal were 25% more likely to stop
smoking in the short and long term. Secondly, a systematic
review [7] suggests that smoking reduction may itself
make cessation more likely, and our data are not contrary
to that. Trials of smoking reduction interventions enrol
people who are making effortful attempts to reduce
smoking. If anything, our data reinforce that causal associ-
ation by showing an apparent dose–response relation
between effortful reduction and subsequent cessation.
They do, however, imply that unwilled reduction that
appears to occur in response to medication may be predic-
tive of cessation only weakly or not at all, and therefore
attempts to tailor medication based on people’s responses
while smoking may be futile. This is unfortunate, particu-
larly because attempts to rescue failing quit attempts after
the quit date appear to be unsuccessful [4,16]. The strat-
egy of selecting an optimum treatment based on pre-
cessation response is attractive but appears, on the basis
of these data, to be unhelpful.
In conclusion, reduced consumption while using nico-
tine replacement and smoking may be a less strong indica-
tor of response to medication than thought previously.
Indeed, it may instead simply reﬂect people’s efforts to
reduce smoking. The search for a reliable indicator of
which cessation medication may prove effective for partic-
ular individuals should continue.
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